Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

14 study records (showing up to 30 per record type)

• Systematic review registration CRD42021276554 Registered protocol, no results here: Review Ongoing
  Effect of Ursodeoxycholic Acid on development of Cholangiocarcinoma in patients with Primary Sclerosing Cholangitis: A Systematic Review
  Condition or outcome area: Cholangiocarcinoma in patients with Primary Sclerosing Cholangitis
  2021-10-02 · Subject: Ursodeoxycholic acid; Ursodiol; ursodiol; 128-13-2; Actigall; ursodeoxycholate; UDCA; Ursofalk; Ursolvan; Ursodesoxycholic acid · open the ingredient record
• Systematic review registration CRD42018087444 Registered protocol, no results here: Review Ongoing
  The efficacy of recombinant epidermal growth factor in the treatment of patients with diabetic foot ulcer compared to control (cure, debridement and antibiotic): systematic review of randomized clinical trials
  Condition or outcome area: Healing of lower limb ulcers in diabetic patients through the intralesioanal application of Human Recombinant Epidermal Growth Factor (hCFR) occurs through stimuli to proliferation of fibroblasts, keratinocytes and vascular endothelial cells, contributing to the formation of healing tissue (Fernández, 2009). The mechanism of action is based on the interaction with specific receptors, located on the cell membrane of a class of cells. The receptor is a glycoprotein with tyrosine kinase activity, w
  2018-02-02 · Subject: Urogastrone; Uroanthelone; Uroenterone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Gastrone, uro-; 62229-50-9; Urogastrone [JAN] · open the ingredient record
• Systematic review registration CRD42022340121 Registered protocol, no results here: Review Ongoing
  Effectiveness of Urea-Based Cream and Pyridoxine(vitamin B6) on Sorafenib-induced Hand-foot Syndrome/skin reaction in hepatocellular carcinoma patients: A Systematic Review and Meta-analysis
  Condition or outcome area: Sorafenib is a multitargeted tyrosine kinase inhibitor, which has been mainly used in the treatment of advanced hepatocellular carcinoma. During the treatment, sorafenib can cause a variety of toxic reactions, such as hand-foot syndrome / skin reaction, hypertension, arterial thromboembolism, diarrhea and so on. Hand-foot Syndrome (HFS)/skin reaction(HFSR) is considered the most clinically significant dermatologic adverse event. For patients, these debilitating symptoms hinder their ability to
  2022-09-10 · Subject: Vitamin b6; Pyridoxal 5'-phosphate(2-); pyridoxal 5'-phosphate(2-); (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl phosphate; 124051-94-1; pyridoxal 5'-phosphate dianion; CHEBI:597326; Q27225781; 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate dianion; 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate(2-) · open the ingredient record
• Systematic review registration CRD42022340121 Registered protocol, no results here: Review Ongoing
  Effectiveness of Urea-Based Cream and Pyridoxine(vitamin B6) on Sorafenib-induced Hand-foot Syndrome/skin reaction in hepatocellular carcinoma patients: A Systematic Review and Meta-analysis
  Condition or outcome area: Sorafenib is a multitargeted tyrosine kinase inhibitor, which has been mainly used in the treatment of advanced hepatocellular carcinoma. During the treatment, sorafenib can cause a variety of toxic reactions, such as hand-foot syndrome / skin reaction, hypertension, arterial thromboembolism, diarrhea and so on. Hand-foot Syndrome (HFS)/skin reaction(HFSR) is considered the most clinically significant dermatologic adverse event. For patients, these debilitating symptoms hinder their ability to
  2022-09-10 · Subject: Vitaminｂ１ · open the ingredient record
• Systematic review registration CRD42022340121 Registered protocol, no results here: Review Ongoing
  Effectiveness of Urea-Based Cream and Pyridoxine(vitamin B6) on Sorafenib-induced Hand-foot Syndrome/skin reaction in hepatocellular carcinoma patients: A Systematic Review and Meta-analysis
  Condition or outcome area: Sorafenib is a multitargeted tyrosine kinase inhibitor, which has been mainly used in the treatment of advanced hepatocellular carcinoma. During the treatment, sorafenib can cause a variety of toxic reactions, such as hand-foot syndrome / skin reaction, hypertension, arterial thromboembolism, diarrhea and so on. Hand-foot Syndrome (HFS)/skin reaction(HFSR) is considered the most clinically significant dermatologic adverse event. For patients, these debilitating symptoms hinder their ability to
  2022-09-10 · Subject: Vitaminｂ · open the ingredient record
• Systematic review registration CRD42022340121 Registered protocol, no results here: Review Ongoing
  Effectiveness of Urea-Based Cream and Pyridoxine(vitamin B6) on Sorafenib-induced Hand-foot Syndrome/skin reaction in hepatocellular carcinoma patients: A Systematic Review and Meta-analysis
  Condition or outcome area: Sorafenib is a multitargeted tyrosine kinase inhibitor, which has been mainly used in the treatment of advanced hepatocellular carcinoma. During the treatment, sorafenib can cause a variety of toxic reactions, such as hand-foot syndrome / skin reaction, hypertension, arterial thromboembolism, diarrhea and so on. Hand-foot Syndrome (HFS)/skin reaction(HFSR) is considered the most clinically significant dermatologic adverse event. For patients, these debilitating symptoms hinder their ability to
  2022-09-10 · Subject: Ur; Urea; urea; 57-13-6; carbamide; Isourea; Carbonyldiamide; Ureophil; Carbonyldiamine; Ureaphil · open the ingredient record
• Systematic review registration CRD42019123848 Registered protocol, no results here: Review Ongoing
  Evaluation of adjuvant VEGFR-targeted tyrosin-kinase-inhibitor therapy in patients with high risk renal cell carcinoma
  Condition or outcome area: High risk localized renal cell carcinoma after surgical resection of the primary tumor.
  2019-06-10 · Subject: Tyrosin; DL-Tyrosine; 556-03-6; H-DL-Tyr-OH; 2-amino-3-(4-hydroxyphenyl)propanoic acid; Tyrosine, DL-; (.+-.)-Tyrosine; MFCD00063074; NSC 205006; A9BAT9B32M · open the ingredient record
• Systematic review registration CRD42022223583 Registered protocol, no results here: Review Ongoing
  Heart failure risk in patients with breast cancer treated with Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab：A Meta-Analysis of Four Randomized Trials
  Condition or outcome area: Breast cancer is the leading cause of cancer in women. 20% of invasive breast cancer is HER2 positive cancer type. Because HER2 is a member of the ErbB tyrosine kinase receptor family, it can mediate tumor progression, thereby affecting the prognosis of breast cancer, and is an invasive index of tumors. Prior to the development of targeted therapy for HER2, HER2 positive breast cancer patients had a higher risk of disease recurrence and reduced survival. From 1998 to the end of 2006, trastuzumab
  2022-06-05 · Subject: Taxol; Paclitaxel; 33069-62-4; P88XT4IS4D; Taxol A; Yewtaxan; Genaxol; Plaxicel; Abraxane; Ebetaxel · open the ingredient record
• Systematic review registration CRD42020162429 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy for advanced epidermal growth factor receptor mutated non-small cell lung cancer: a systematic review and meta-analysis
  Condition or outcome area: Advanced non-small cell lung cancer (NSCLC)
  2020-07-14 · Subject: Urogastrone; Uroanthelone; Uroenterone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Gastrone, uro-; 62229-50-9; Urogastrone [JAN] · open the ingredient record
• Systematic review registration CRD42019131970 Registered protocol, no results here: Review Ongoing
  Systematic review and planned meta-analysis of controlled clinical trials to examine clinical efficacy and safety of treatment with small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in comparison with control group in patients with metastatic human epidermal growth factor receptor (HER)2-positive breast cancer
  Condition or outcome area: Metastatic HER2-positive breast cancer
  2019-07-12 · Subject: Urogastrone; Uroanthelone; Uroenterone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Gastrone, uro-; 62229-50-9; Urogastrone [JAN] · open the ingredient record
• Systematic review registration CRD42016033054 Registered protocol, no results here: Review Ongoing
  The efficacy of inosine pranobex in non-HIV and non-cancer clinical conditions
  Condition or outcome area: Literature data concerning studies related to clinical applications of Inosine pranobex in patients with the non-HIV and non-tumor diseases, including human papillomavirus (HPV, genital warts), herpes simplex virus (HSV), influenza, zoster, respiratory tract viral infections, recurrent infections, measles, hepatitis, chronic fatigue, poststroke infection, subacute sclerosing panencephalitis (SSPE), amyotrophic lateral sclerosis, multiple sclerosis, alopecia areata/totalis, hearing loss will be
  2016-01-19 · Subject: Nos; 6-(2-Fluoropropyl)-4-methylpyridin-2-amine; 1146620-35-0; R1W11H9AUK; UNII-R1W11H9AUK; CHEMBL450726; 2-Pyridinamine, 6-(2-fluoropropyl)-4-methyl-; 6-(2-(Fluoro)-propyl)-4-methyl-2-pyridinamine; 6-(2-fluoropropyl)-4-methyl-2-PyridinamineOxalicacid; SCHEMBL13040574 · open the ingredient record
• Systematic review registration CRD42016033054 Registered protocol, no results here: Review Ongoing
  The efficacy of inosine pranobex in non-HIV and non-cancer clinical conditions
  Condition or outcome area: Literature data concerning studies related to clinical applications of Inosine pranobex in patients with the non-HIV and non-tumor diseases, including human papillomavirus (HPV, genital warts), herpes simplex virus (HSV), influenza, zoster, respiratory tract viral infections, recurrent infections, measles, hepatitis, chronic fatigue, poststroke infection, subacute sclerosing panencephalitis (SSPE), amyotrophic lateral sclerosis, multiple sclerosis, alopecia areata/totalis, hearing loss will be
  2016-01-19 · Subject: Inosine; 58-63-9; Hypoxanthosine; Ribonosine; Atorel; Oxiamin; Hypoxanthine riboside; Trophicardyl; Selfer; Pantholic-L · open the ingredient record
• Systematic review registration CRD42022287550 Registered protocol, no results here: Review Ongoing
  Caffeine-containing multi-ingredient supplements to improve body composition, exercise capacity and performance, substrate utilization and psychophysical outcomes: a comprehensive systematic review and meta-analyses
  Condition or outcome area: Multi-ingredient pre-workout supplements (MIPS) is a large group of dietary supplements, that contain broad range of various active ingredients. They are becoming more and more popular among different age- and training level-groups of physically active people and athletes. Among the most popular ingredients of MIPS there are: beta-alanine, caffeine, citrulline, tyrosine, creatine, niacin, arginine or vitamin B12. Particular MIPS preparations varies considerably between each other regarding type
  2022-02-04 · Subject: Caffeine; 58-08-2; Guaranine; 1,3,7-Trimethylxanthine; Methyltheobromine; Theine; Thein; Cafeina; Koffein; Mateina · open the ingredient record
• Systematic review registration CRD42016045492 Registered protocol, no results here: Review Ongoing
  Bile acid derivatives for people with primary sclerosing cholangitis [Cochrane Protocol]
  Condition or outcome area: The Cochrane Hepato-Biliary Group
  2016-08-08 · Subject: Bile acid; Bile Acid; Bile salt; CHEBI:22868; Gallensaeure; Gallensaeuren; 5beta-bile acid; 5beta-bile acids; Acid, Bile; CHEBI:3098 · open the ingredient record